Indeed, the initial evidence supporting a tumor-suppressor role for the TGF-β in several models, and the findings that first-generation TGFBR1 inhibitors triggered overt cardiac toxicity in preclinical studies [96], have greatly diminished the interests of pharmaceutical industry/research in this approach. Here, TGFB1 is linked to neoplasm.